EMJ Hematology 11 [Supplement 3] . 2023

This article highlights key insights from a symposium on treatment options for patients with relapsed/refractory diffuse large B cell lymphomas (DLBCL) who are not eligible for autologous stem cell transplant, and where chimeric antigen receptor T cell therapy is not appropriate. It was delivered at the International Conference on Malignant Lymphoma (ICML) Congress, which took place in Lugano, Switzerland, on 13th June 2023. The expert panellists explored treatment decisions for different patients and emphasised the need for multidisciplinary team input and patient and caregiver inclusion.